Ocrevus is the first treatment approved for primary progressive multiple sclerosis (PPMS); it’s also indicated for relapsing (RMS). Ocrevus is given as an intravenous (IV) infusion. In both forms of MS, Phase III studies indicated that Ocrevus slowed disability and reduce signs of disease activity in the brain (MRI lesions).